Shire Acquires Lotus Tissue Repair, Inc

UK pharma outfit, Shire plc , is to acquire Lotus Tissue Repair, Inc., a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is a devastating orphan disease for which there is no currently approved treatment option other than palliative care.